![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.233.382![]() |
Chemical and physical data | |
Formula | C22H23IN2O |
Molar mass | 458.343 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
AM-2233 is a drug that acts as a highly potentfull agonist for thecannabinoid receptors, with aKi of 1.8 nM atCB1 and 2.2 nM atCB2 as the active (R)enantiomer.[1] It was developed as a selectiveradioligand for the cannabinoid receptors and has been used as its131I derivative for mapping the distribution of the CB1 receptor in the brain.[2][3][4][5][6][7] AM-2233 was found to fully substitute forTHC in rats, with a potency lower than that ofJWH-018 but higher thanWIN 55,212-2.[8]
It is notable for inducingtinnitus,[9] though the reasons for this are unclear and may provide valuable insight into tinnitus research.
As of October 2015 AM-2233 is a controlled substance in China.[10]
![]() | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |